Abstract
Influenza is associated with a significant economic burden on both society and the individual, resulting in considerable healthcare costs and loss of productivity, as well as intangible costs such as suffering, grief and social disruption. The incidence and severity of influenza infection depend, at least in part, on the age and health status of the population. For example, the incidence of influenza is relatively high among children and young adults, but serious complications are much more likely to occur among the very young (<1 year of age) and the elderly (>65 years of age). School absenteeism tends to peak in the first half of a typical 6- to 8-week influenza epidemic, followed by workplace absenteeism in the latter half as school-aged children pass the infection to family members.
Cost-of-illness studies are used by policy-makers to justify budgets and set priorities for prevention programmes, research and other expenditures. On the basis of German Sickness Fund data, recent estimates indicate that the cost of an influenza epidemic in that country is approximately 2 billion Deutschmarks (≈$US1.4 billion). The bulk of these costs reflects indirect costs associated with lost productivity, a finding also noted in an earlier French cost-of-illness study of influenza. Thus, the main economic burden of influenza falls on infected individuals, their employers and their relatives.Methodology used in cost-of-illness studies can be quite variable. For example, two main approaches are used in measuring indirect costs (human capital and willingness to pay), although there is controversy as to which is the preferred method. Thus, investigators involved in cost-of-illness studies must be explicit regarding study methodology in order to allow for appropriate interpretation of study results by interested parties.
Article PDF
Similar content being viewed by others
References
Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–1976. N Engl J Med 1978; 298: 587–92
Glezen WP, Payne AA, Snyder DN, et al. Mortality and influenza. J Infect Dis 1982; 146: 313–21
Office of Technology Assessment. Washington, 1984
Statistical Yearbook for Germany. Frankfurt, 1997)
Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 62–6
Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996; 9 Suppl. 3: 26–33
Taber LH, Paredes A, Glezen WP, et al. Infectionwith influenza A/Victoria virus in Houston families, 1976. J Hyg (Lond) 1981; 86: 303–13
Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as ameasure of impact of epidemic influenza. Am J Epidemiol 1985; 122: 468–76
Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82 Suppl. 6A: 15–9
Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87 (12): 1944–50
Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77 (6): 712–5
Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982; 142: 85–9
Smith A. The socioeconomic aspects and behavioural effects of influenza. In: Wood C, editor. Influenza: strategies for prevention. London: Royal Society of Medicine, 1988: 46–52
Schoenbaum SC. Impact of influenza in persons and populations. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza, III. New York: Elsevier Science BV, 1996: 17–25
Kavet J. A perspective on the significance of pandemic influenza. Am J Public Health 1977; 67: 1063–70
Treanor JJ. New approaches to influenza vaccine high doses, neuraminidase vaccines, alternative substrates, and new adjuvants. Infect Med 1998; 15: 487–92
Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Inf 1993; 110: 145–60
Smith AP, Thomas M, Brockman P, et al. Effect of influenza virus B infection on human performance. BMJ 1993; 306: 760–1
Smith AP. Colds, flu and performance. Occup Health Rev 1995; Nov/Dec: 29–33
Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. Arch Intern Med 1998; 158: 645–50
Johanneson M, Jonsson B. Economic evaluation in health care: is there a role for cost benefit analysis? Health Policy 1991; 17: 1–23
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szucs, T. Influenza. Pharmacoeconomics 16 (Suppl 1), 27–32 (1999). https://doi.org/10.2165/00019053-199916001-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199916001-00004